NCT03114319 - Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

227

Participants

Timeline

Start Date

May 26, 2017

Primary Completion Date

July 4, 2025

Study Completion Date

July 4, 2025

Conditions

Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC)KRAS G12-mutant NSCLCEsophageal Squamous Cell Cancer (SCC)Head/Neck SCCMelanomaAdvanced Gastrointestinal Stromal Tumors (GIST)Advanced NRAS/BRAFT wt Cutaneous Melanoma

Interventions

DRUG

TNO155

TNO155 for oral administration

DRUG

TNO155 in combination with EGF816 (nazartinib)

TNO155 for oral administration; EGF816 (nazartinib) for oral administration

Trial Locations (18)

10002

Novartis Investigative Site, Taipei

10065

Memorial Sloane Ketterin Cancer Ctr, New York

20141

Novartis Investigative Site, Milan

28009

Novartis Investigative Site, Madrid

28034

Novartis Investigative Site, Madrid

28040

Novartis Investigative Site, Madrid

33612

H Lee Moffitt Cancer Center and Research Institute, Tampa

37221

Sarah Cannon Research Institute, Nashville

168583

Novartis Investigative Site, Singapore

02215

Dana Farber Cancer Center, Boston

M5G 2M9

Novartis Investigative Site, Toronto

650-0017

Novartis Investigative Site, Kobe

3015 GD

Novartis Investigative Site, Rotterdam

1066 CX

Novartis Investigative Site, Amsterdam

03080

Novartis Investigative Site, Seoul

05505

Novartis Investigative Site, Seoul

08907

Novartis Investigative Site, L'Hospitalet de Llobregat

08035

Novartis Investigative Site, Barcelona